Ushbu ish iqtibos qilgan ishlar

32 ta ish

Ish: Catumaxomab

1. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

   Peter Ruf, Michael Kluge, Michael Jäger +7

   Maqola20103 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.913630

2. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

   Peter Ruf, Horst Lindhofer

   Maqola20013 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.913633

3. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

   Alexander Burges, Pauline Wimberger, Carolin Kümper +15

   Maqola20073 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.913648

4. The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

   Markus Münz, Patrick A. Baeuerle, Olivier Gires

   Sharh maqola20092 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.252098

5. Immunotherapy and chemotherapy — a practical partnership

   Richard Lake, Bruce Robinson

   Sharh maqola20052 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.677837

6. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

   Constantin N. Baxevanis, Sonia A. Perez, Michael Papamichail

   Sharh maqola20082 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.719170

7. Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

   Reinhard Zeidler, G. Reisbach, Barbara Wollenberg +4

   Maqola19992 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.913629

8. Pattern and prognostic factors in patients with malignant ascites: a retrospective study

   Abraham Ayantunde, SL Parsons

   Maqola20072 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.913645

9. Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)

   Rainer Riesenberg, Alexander Büchner, Heike Pohla +1

   Maqola20012 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.913646

10. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913631

11. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913632

12. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913634

13. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913635

14. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913636

15. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913637

16. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913638

17. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913639

18. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913640

19. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913641

20. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913642

21. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913643

22. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913644

23. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913647

24. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913649

25. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.913650